From the Editor - Pharmaceutical Executive


From the Editor
The industry and its issues, from editor-in-chief William Looney.

The Community Ethic

March 1, 2014

Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.

A Spark From GSK

February 1, 2014

Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.

Russian Innovation: A Higher Mark

February 1, 2014

For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products

For Russia—Tough Love

January 21, 2014

Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.

Big Stakes in Small Things

December 1, 2013

New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.

Payers: Late for the Party?

November 1, 2013

Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.

Taking Stock: Notes on the Industry Audit

October 1, 2013

Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."

Trying to Control Pharma Costs?

September 1, 2013

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.

One Company—One Moment

August 1, 2013

The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.


Click here